Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

This study is a prospective, open-label, multicenter study in previously untreated participants with CD20-positive DLBCL. Orelabrutinib combined with standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) for newly diagnosed diffuse large B-cell lymphoma (DLBCL). The primary objective is to explore the 1-year progression-free survival (PFS) of orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT in newly diagnosed DLBCL.

Trial Details

NCT ID
NCT07680933
Phase
PHASE2
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • Signed informed consent;
  • Age 18-80 years at the time of signing informed consent, and willingness to comply with the study protocol procedures;
  • Pathologically confirmed CD20-positive DLBCL;
  • ④ IPI score of 2-5;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →